Insider Selling: Emergent Biosolutions, Inc. (EBS) Director Sells 10,776 Shares of Stock

Emergent Biosolutions, Inc. (NYSE:EBS) Director Jerome M. Hauer sold 10,776 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $35.83, for a total transaction of $386,104.08. Following the completion of the transaction, the director now owns 29,421 shares in the company, valued at approximately $1,054,154.43. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Emergent Biosolutions, Inc. (EBS) traded down 1.99% on Thursday, reaching $35.49. 210,426 shares of the company’s stock traded hands. The stock’s 50 day moving average is $35.00 and its 200 day moving average is $31.63. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of 22.61 and a beta of 1.22. Emergent Biosolutions, Inc. has a 52-week low of $24.47 and a 52-week high of $36.95.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.26 by $0.13. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The business had revenue of $100.77 million during the quarter, compared to analyst estimates of $111.57 million. During the same quarter last year, the business earned ($0.05) earnings per share. Emergent Biosolutions’s revenue for the quarter was up 10.4% on a year-over-year basis. On average, equities research analysts predict that Emergent Biosolutions, Inc. will post $1.55 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/08/17/insider-selling-emergent-biosolutions-inc-ebs-director-sells-10776-shares-of-stock.html.

Several hedge funds have recently bought and sold shares of EBS. Public Employees Retirement System of Ohio increased its stake in Emergent Biosolutions by 2.6% in the second quarter. Public Employees Retirement System of Ohio now owns 36,866 shares of the biopharmaceutical company’s stock worth $1,250,000 after buying an additional 917 shares during the period. Piedmont Investment Advisors LLC acquired a new stake in Emergent Biosolutions during the second quarter worth about $255,000. Ameritas Investment Partners Inc. increased its stake in Emergent Biosolutions by 23.2% in the second quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 587 shares during the period. The Manufacturers Life Insurance Company increased its stake in Emergent Biosolutions by 2.5% in the second quarter. The Manufacturers Life Insurance Company now owns 631,304 shares of the biopharmaceutical company’s stock worth $21,409,000 after buying an additional 15,314 shares during the period. Finally, Macquarie Group Ltd. increased its stake in Emergent Biosolutions by 0.8% in the second quarter. Macquarie Group Ltd. now owns 25,969 shares of the biopharmaceutical company’s stock worth $881,000 after buying an additional 197 shares during the period. Institutional investors own 85.54% of the company’s stock.

Several research analysts have weighed in on EBS shares. Zacks Investment Research lowered shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. BidaskClub upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $44.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

What are top analysts saying about Emergent Biosolutions Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Emergent Biosolutions Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit